PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS IN PATIENTS FAILING INTEGRASE INHIBITOR-BASED REGIMEN BY ULTRA-DEEP SEQUENCING

Integrase strand transfer inhibitors (INSTIs) are currently recommended byinternational guidelines as first-line therapy in antiretroviral (ARV)-naïve and experienced HIV-1infected patients. This study aimed at evaluating prevalence at failure of INSTI resistant variants andimpact of baseline minority resistant variants (MiRVs) on virological response to INSTI-basedregimen.